$AVM Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AMAG PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in AMAG PHARMACEUTICALS, INC.. Get notifications about new insider transactions in AMAG PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 ... 11 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | JOHNSON DAVID EDWARD | Director | Option Exercise | A | 8.52 | 21,289 | 181,382 | 21,289 | |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | JOHNSON DAVID EDWARD | Director | Grant | A | 0.00 | 10,269 | 0 | 14,676 | 4.4 K to 14.7 K (+233.02 %) |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | Phillips Anne M. | Director | Option Exercise | A | 8.52 | 21,289 | 181,382 | 21,289 | |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | Phillips Anne M. | Director | Grant | A | 0.00 | 10,269 | 0 | 18,949 | 8.7 K to 18.9 K (+118.31 %) |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Option Exercise | A | 8.52 | 21,289 | 181,382 | 21,289 | |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Grant | A | 0.00 | 10,269 | 0 | 41,473 | 31.2 K to 41.5 K (+32.91 %) |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Option Exercise | A | 8.52 | 21,289 | 181,382 | 21,289 | |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Grant | A | 0.00 | 10,269 | 0 | 37,362 | 27.1 K to 37.4 K (+37.90 %) |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Option Exercise | A | 8.52 | 21,289 | 181,382 | 21,289 | |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Grant | A | 0.00 | 10,269 | 0 | 35,090 | 24.8 K to 35.1 K (+41.37 %) |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | FONTEYNE PAUL R. | Director | Option Exercise | A | 8.52 | 21,289 | 181,382 | 21,289 | |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | FONTEYNE PAUL R. | Director | Grant | A | 0.00 | 10,269 | 0 | 14,676 | 4.4 K to 14.7 K (+233.02 %) |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | O'Brien Kathrine | Director | Option Exercise | A | 8.52 | 21,289 | 181,382 | 21,289 | |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | O'Brien Kathrine | Director | Grant | A | 0.00 | 10,269 | 0 | 18,949 | 8.7 K to 18.9 K (+118.31 %) |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Option Exercise | A | 8.52 | 21,289 | 181,382 | 21,289 | |
Jun 04 2020 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Grant | A | 0.00 | 10,269 | 0 | 43,898 | 33.6 K to 43.9 K (+30.54 %) |
Apr 30 2020 | AVM | AMAG PHARMACEUTICA ... | Myers Scott Dunseth | President & CEO | Option Exercise | A | 8.20 | 1,000,000 | 8,200,000 | 1,000,000 | |
Apr 06 2020 | AVM | AMAG PHARMACEUTICA ... | Schick Kelly | Chief Human Resourc ... | Payment of Exercise | F | 6.18 | 79 | 488 | 28,155 | 28.2 K to 28.2 K (-0.28 %) |
Apr 06 2020 | AVM | AMAG PHARMACEUTICA ... | Casciano Anthony | Chief Commercial Of ... | Payment of Exercise | F | 6.14 | 1,468 | 9,014 | 76,741 | 78.2 K to 76.7 K (-1.88 %) |
Mar 18 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 4.87 | 24,000 | 116,880 | 348,000 | 324 K to 348 K (+7.41 %) |
Mar 18 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 4.87 | 24,000 | 116,880 | 348,000 | 324 K to 348 K (+7.41 %) |
Mar 12 2020 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | COO & CFO | Option Exercise | A | 7.27 | 45,000 | 327,150 | 45,000 | |
Mar 12 2020 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | COO & CFO | Grant | A | 0.00 | 30,000 | 0 | 98,659 | 68.7 K to 98.7 K (+43.69 %) |
Mar 12 2020 | AVM | AMAG PHARMACEUTICA ... | Schick Kelly | Chief Human Resourc ... | Option Exercise | A | 7.27 | 17,000 | 123,590 | 17,000 | |
Mar 12 2020 | AVM | AMAG PHARMACEUTICA ... | Schick Kelly | Chief Human Resourc ... | Grant | A | 0.00 | 13,000 | 0 | 28,234 | 15.2 K to 28.2 K (+85.34 %) |
Mar 12 2020 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | CBO, General Counse ... | Option Exercise | A | 7.27 | 35,000 | 254,450 | 35,000 | |
Mar 12 2020 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | CBO, General Counse ... | Grant | A | 0.00 | 25,000 | 0 | 92,244 | 67.2 K to 92.2 K (+37.18 %) |
Mar 12 2020 | AVM | AMAG PHARMACEUTICA ... | Casciano Anthony | Chief Commercial Of ... | Option Exercise | A | 7.27 | 40,000 | 290,800 | 40,000 | |
Mar 12 2020 | AVM | AMAG PHARMACEUTICA ... | Casciano Anthony | Chief Commercial Of ... | Grant | A | 0.00 | 25,000 | 0 | 78,209 | 53.2 K to 78.2 K (+46.98 %) |
Mar 04 2020 | AVM | AMAG PHARMACEUTICA ... | Casciano Anthony | Chief Commercial Of ... | Payment of Exercise | F | 7.75 | 924 | 7,161 | 53,209 | 54.1 K to 53.2 K (-1.71 %) |
Mar 04 2020 | AVM | AMAG PHARMACEUTICA ... | Schick Kelly | Chief Human Resourc ... | Payment of Exercise | F | 7.75 | 358 | 2,775 | 15,234 | 15.6 K to 15.2 K (-2.30 %) |
Mar 04 2020 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Payment of Exercise | F | 7.75 | 4,451 | 34,495 | 424,612 | 429.1 K to 424.6 K (-1.04 %) |
Mar 04 2020 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | CBO, General Counse ... | Payment of Exercise | F | 7.75 | 1,138 | 8,820 | 67,244 | 68.4 K to 67.2 K (-1.66 %) |
Mar 04 2020 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | COO & CFO | Payment of Exercise | F | 7.75 | 1,021 | 7,913 | 68,659 | 69.7 K to 68.7 K (-1.47 %) |
Mar 04 2020 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | Chief Medical Offic ... | Payment of Exercise | F | 7.75 | 1,333 | 10,331 | 73,044 | 74.4 K to 73 K (-1.79 %) |
Feb 27 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 8.29 | 12,000 | 99,480 | 324,000 | 312 K to 324 K (+3.85 %) |
Feb 27 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 8.29 | 24,000 | 198,960 | 312,000 | 288 K to 312 K (+8.33 %) |
Feb 25 2020 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | COO & CFO | Payment of Exercise | F | 8.84 | 1,386 | 12,252 | 77,180 | 78.6 K to 77.2 K (-1.76 %) |
Feb 25 2020 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | COO & CFO | Payment of Exercise | F | 9.50 | 867 | 8,237 | 78,566 | 79.4 K to 78.6 K (-1.09 %) |
Feb 25 2020 | AVM | AMAG PHARMACEUTICA ... | Casciano Anthony | Chief Commercial Of ... | Payment of Exercise | F | 8.84 | 881 | 7,788 | 58,133 | 59 K to 58.1 K (-1.49 %) |
Feb 25 2020 | AVM | AMAG PHARMACEUTICA ... | Casciano Anthony | Chief Commercial Of ... | Payment of Exercise | F | 9.50 | 463 | 4,399 | 59,014 | 59.5 K to 59 K (-0.78 %) |
Feb 25 2020 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | Chief Medical Offic ... | Payment of Exercise | F | 8.84 | 1,155 | 10,210 | 81,877 | 83 K to 81.9 K (-1.39 %) |
Feb 25 2020 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | Chief Medical Offic ... | Payment of Exercise | F | 9.50 | 867 | 8,237 | 83,032 | 83.9 K to 83 K (-1.03 %) |
Feb 25 2020 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | CBO, General Counse ... | Payment of Exercise | F | 8.84 | 2,206 | 19,501 | 75,882 | 78.1 K to 75.9 K (-2.83 %) |
Feb 25 2020 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | CBO, General Counse ... | Payment of Exercise | F | 9.50 | 867 | 8,237 | 78,088 | 79 K to 78.1 K (-1.10 %) |
Jan 28 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 9.41 | 8,000 | 75,280 | 288,000 | 280 K to 288 K (+2.86 %) |
Jan 28 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 9.43 | 8,000 | 75,440 | 4,120,000 | 4.1 M to 4.1 M (+0.19 %) |
Jan 28 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 9.72 | 40,000 | 388,800 | 280,000 | 240 K to 280 K (+16.67 %) |
Jan 28 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 9.58 | 34,000 | 325,720 | 4,112,000 | 4.1 M to 4.1 M (+0.83 %) |
Jan 13 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 11.64 | 18,000 | 209,520 | 4,078,000 | 4.1 M to 4.1 M (+0.44 %) |
Jan 13 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 12.33 | 12,466 | 153,706 | 4,060,000 | 4 M to 4.1 M (+0.31 %) |
Jan 13 2020 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Sell | S | 12.43 | 12,466 | 154,952 | 4,047,534 | 4.1 M to 4 M (-0.31 %) |
Oct 10 2019 | AVM | AMAG PHARMACEUTICA ... | JOHNSON DAVID EDWARD | Director | Option Exercise | A | 11.58 | 9,452 | 109,454 | 9,452 | |
Oct 10 2019 | AVM | AMAG PHARMACEUTICA ... | JOHNSON DAVID EDWARD | Director | Option Exercise | A | 11.58 | 6,000 | 69,480 | 6,000 | |
Oct 10 2019 | AVM | AMAG PHARMACEUTICA ... | JOHNSON DAVID EDWARD | Director | Grant | A | 0.00 | 4,407 | 0 | 4,407 | 0 to 4.4 K |
Oct 10 2019 | AVM | AMAG PHARMACEUTICA ... | FONTEYNE PAUL R. | Director | Option Exercise | A | 11.58 | 9,452 | 109,454 | 9,452 | |
Oct 10 2019 | AVM | AMAG PHARMACEUTICA ... | FONTEYNE PAUL R. | Director | Option Exercise | A | 11.58 | 6,000 | 69,480 | 6,000 | |
Oct 10 2019 | AVM | AMAG PHARMACEUTICA ... | FONTEYNE PAUL R. | Director | Grant | A | 0.00 | 4,407 | 0 | 4,407 | 0 to 4.4 K |
Sep 06 2019 | AVM | AMAG PHARMACEUTICA ... | Casciano Anthony | Chief Commercial Of ... | Payment of Exercise | F | 11.83 | 982 | 11,617 | 59,477 | 60.5 K to 59.5 K (-1.62 %) |
Sep 06 2019 | AVM | AMAG PHARMACEUTICA ... | Casciano Anthony | Chief Commercial Of ... | Payment of Exercise | F | 11.24 | 393 | 4,417 | 60,459 | 60.9 K to 60.5 K (-0.65 %) |
Aug 09 2019 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 7.43 | 40,000 | 297,200 | 240,000 | 200 K to 240 K (+20.00 %) |
Aug 09 2019 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 7.32 | 260,000 | 1,903,200 | 4,060,000 | 3.8 M to 4.1 M (+6.84 %) |
Aug 09 2019 | AVM | AMAG PHARMACEUTICA ... | Camber Capital Management LP | Buy | P | 9.18 | 3,400 | 31,206 | 4,390,000 | 4.4 M to 4.4 M (+0.08 %) | |
Aug 09 2019 | AVM | AMAG PHARMACEUTICA ... | Camber Capital Management LP | Buy | P | 8.94 | 26,600 | 237,791 | 4,386,600 | 4.4 M to 4.4 M (+0.61 %) | |
Aug 09 2019 | AVM | AMAG PHARMACEUTICA ... | Camber Capital Management LP | Buy | P | 7.58 | 4,000 | 30,300 | 4,360,000 | 4.4 M to 4.4 M (+0.09 %) | |
Aug 09 2019 | AVM | AMAG PHARMACEUTICA ... | Camber Capital Management LP | Buy | P | 7.74 | 50,000 | 387,000 | 4,356,000 | 4.3 M to 4.4 M (+1.16 %) | |
Aug 09 2019 | AVM | AMAG PHARMACEUTICA ... | Camber Capital Management LP | Buy | P | 7.79 | 301,000 | 2,343,496 | 4,306,000 | 4 M to 4.3 M (+7.52 %) | |
Jun 27 2019 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 9.47 | 20,000 | 189,400 | 200,000 | 180 K to 200 K (+11.11 %) |
Jun 27 2019 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 9.52 | 44,000 | 418,880 | 3,800,000 | 3.8 M to 3.8 M (+1.17 %) |
Jun 27 2019 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 9.13 | 120,000 | 1,095,600 | 3,756,000 | 3.6 M to 3.8 M (+3.30 %) |
Jun 27 2019 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 8.86 | 30,000 | 265,800 | 180,000 | 150 K to 180 K (+20.00 %) |
Jun 27 2019 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 8.85 | 25,000 | 221,250 | 150,000 | 125 K to 150 K (+20.00 %) |
Jun 27 2019 | AVM | AMAG PHARMACEUTICA ... | ARMISTICE CAPITAL, LLC | 10% Owner | Buy | P | 8.59 | 259,016 | 2,224,947 | 3,636,000 | 3.4 M to 3.6 M (+7.67 %) |
May 29 2019 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | Chief Medical Offic ... | Buy | P | 9.91 | 10,000 | 99,100 | 81,399 | 71.4 K to 81.4 K (+14.01 %) |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Option Exercise | A | 10.78 | 17,326 | 186,774 | 17,326 | |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Grant | A | 0.00 | 8,116 | 0 | 26,354 | 18.2 K to 26.4 K (+44.50 %) |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Option Exercise | A | 10.78 | 17,326 | 186,774 | 17,326 | |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Grant | A | 0.00 | 8,116 | 0 | 31,204 | 23.1 K to 31.2 K (+35.15 %) |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Option Exercise | A | 10.78 | 17,326 | 186,774 | 17,326 | |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Grant | A | 0.00 | 8,116 | 0 | 29,229 | 21.1 K to 29.2 K (+38.44 %) |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Option Exercise | A | 10.78 | 17,326 | 186,774 | 17,326 | |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Grant | A | 0.00 | 8,116 | 0 | 24,821 | 16.7 K to 24.8 K (+48.58 %) |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | Phillips Anne M. | Director | Option Exercise | A | 10.78 | 17,326 | 186,774 | 17,326 | |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | Phillips Anne M. | Director | Grant | A | 0.00 | 8,116 | 0 | 8,680 | 564 to 8.7 K (+1,439.01 %) |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Option Exercise | A | 10.78 | 17,326 | 186,774 | 17,326 | |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Grant | A | 0.00 | 8,116 | 0 | 27,093 | 19 K to 27.1 K (+42.77 %) |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | O'Brien Kathrine | Director | Option Exercise | A | 10.78 | 17,326 | 186,774 | 17,326 | |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | O'Brien Kathrine | Director | Grant | A | 0.00 | 8,116 | 0 | 8,680 | 564 to 8.7 K (+1,439.01 %) |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Option Exercise | A | 10.78 | 17,326 | 186,774 | 17,326 | |
May 20 2019 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Grant | A | 0.00 | 8,116 | 0 | 33,629 | 25.5 K to 33.6 K (+31.81 %) |
May 09 2019 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Buy | P | 10.70 | 10,000 | 107,000 | 490,056 | 480.1 K to 490.1 K (+2.08 %) |
May 09 2019 | AVM | AMAG PHARMACEUTICA ... | Bolgiano Elizabeth Scott | Chief Human Resourc ... | Buy | P | 10.93 | 5,000 | 54,650 | 74,847 | 69.8 K to 74.8 K (+7.16 %) |
May 01 2019 | AVM | AMAG PHARMACEUTICA ... | Butcher James Alan | EVP, Chief Business ... | Payment of Exercise | F | 11.16 | 2,790 | 31,136 | 50,628 | 53.4 K to 50.6 K (-5.22 %) |
Apr 12 2019 | AVM | AMAG PHARMACEUTICA ... | Phillips Anne M. | Director | Option Exercise | A | 12.92 | 1,200 | 15,504 | 1,200 | |
Apr 12 2019 | AVM | AMAG PHARMACEUTICA ... | Phillips Anne M. | Director | Option Exercise | A | 12.92 | 6,000 | 77,520 | 6,000 | |
Apr 12 2019 | AVM | AMAG PHARMACEUTICA ... | Phillips Anne M. | Director | Grant | A | 0.00 | 564 | 0 | 564 | 0 to 564 |
Apr 12 2019 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Payment of Exercise | F | 12.47 | 1,964 | 24,491 | 79,433 | 81.4 K to 79.4 K (-2.41 %) |
Apr 12 2019 | AVM | AMAG PHARMACEUTICA ... | O'Brien Kathrine | Director | Option Exercise | A | 12.92 | 1,200 | 15,504 | 1,200 | |
Apr 12 2019 | AVM | AMAG PHARMACEUTICA ... | O'Brien Kathrine | Director | Option Exercise | A | 12.92 | 6,000 | 77,520 | 6,000 | |
Apr 12 2019 | AVM | AMAG PHARMACEUTICA ... | O'Brien Kathrine | Director | Grant | A | 0.00 | 564 | 0 | 564 | 0 to 564 |
Apr 05 2019 | AVM | AMAG PHARMACEUTICA ... | Casciano Anthony | Chief Commercial Of ... | Option Exercise | A | 13.03 | 25,000 | 325,750 | 25,000 | |
Apr 05 2019 | AVM | AMAG PHARMACEUTICA ... | Casciano Anthony | Chief Commercial Of ... | Grant | A | 0.00 | 15,000 | 0 | 60,852 | 45.9 K to 60.9 K (+32.71 %) |
Mar 11 2019 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Sell | S | 14.01 | 1,425 | 19,964 | 78,955 | 80.4 K to 79 K (-1.77 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Bolgiano Elizabeth Scott | Chief Human Resourc ... | Option Exercise | A | 15.51 | 20,000 | 310,200 | 20,000 | |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Bolgiano Elizabeth Scott | Chief Human Resourc ... | Grant | A | 0.00 | 7,500 | 0 | 71,474 | 64 K to 71.5 K (+11.72 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Bolgiano Elizabeth Scott | Chief Human Resourc ... | Grant | A | 0.00 | 7,500 | 0 | 63,974 | 56.5 K to 64 K (+13.28 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Butcher James Alan | EVP, Chief Business ... | Option Exercise | A | 15.51 | 25,000 | 387,750 | 25,000 | |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Butcher James Alan | EVP, Chief Business ... | Grant | A | 0.00 | 15,000 | 0 | 53,418 | 38.4 K to 53.4 K (+39.04 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Butcher James Alan | EVP, Chief Business ... | Grant | A | 0.00 | 10,000 | 0 | 38,418 | 28.4 K to 38.4 K (+35.19 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | Chief Medical Offic ... | Option Exercise | A | 15.51 | 25,000 | 387,750 | 25,000 | |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | Chief Medical Offic ... | Grant | A | 0.00 | 15,000 | 0 | 73,606 | 58.6 K to 73.6 K (+25.59 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | Chief Medical Offic ... | Grant | A | 0.00 | 10,000 | 0 | 58,606 | 48.6 K to 58.6 K (+20.57 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Option Exercise | A | 15.51 | 70,000 | 1,085,700 | 70,000 | |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Grant | A | 0.00 | 132,000 | 0 | 488,058 | 356.1 K to 488.1 K (+37.07 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Grant | A | 0.00 | 31,000 | 0 | 356,058 | 325.1 K to 356.1 K (+9.54 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Option Exercise | A | 15.51 | 25,000 | 387,750 | 25,000 | |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 20,000 | 0 | 82,461 | 62.5 K to 82.5 K (+32.02 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 12,000 | 0 | 62,461 | 50.5 K to 62.5 K (+23.78 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Option Exercise | A | 15.51 | 25,000 | 387,750 | 25,000 | |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Grant | A | 0.00 | 12,000 | 0 | 82,512 | 70.5 K to 82.5 K (+17.02 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Grant | A | 0.00 | 20,000 | 0 | 70,512 | 50.5 K to 70.5 K (+39.59 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Option Exercise | A | 15.51 | 25,000 | 387,750 | 25,000 | |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Grant | A | 0.00 | 12,000 | 0 | 85,787 | 73.8 K to 85.8 K (+16.26 %) |
Feb 27 2019 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Grant | A | 0.00 | 12,000 | 0 | 73,787 | 61.8 K to 73.8 K (+19.42 %) |
Feb 26 2019 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Payment of Exercise | F | 15.51 | 2,957 | 45,863 | 325,058 | 328 K to 325.1 K (-0.90 %) |
Feb 26 2019 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | Chief Medical Offic ... | Payment of Exercise | F | 15.51 | 869 | 13,478 | 48,606 | 49.5 K to 48.6 K (-1.76 %) |
Feb 26 2019 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Payment of Exercise | F | 15.51 | 982 | 15,231 | 61,787 | 62.8 K to 61.8 K (-1.56 %) |
Feb 26 2019 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Payment of Exercise | F | 15.51 | 869 | 13,478 | 50,461 | 51.3 K to 50.5 K (-1.69 %) |
Feb 26 2019 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Payment of Exercise | F | 15.51 | 869 | 13,478 | 50,512 | 51.4 K to 50.5 K (-1.69 %) |
Feb 26 2019 | AVM | AMAG PHARMACEUTICA ... | Bolgiano Elizabeth Scott | Chief Human Resourc ... | Payment of Exercise | F | 15.51 | 695 | 10,779 | 56,474 | 57.2 K to 56.5 K (-1.22 %) |
Jan 08 2019 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Payment of Exercise | F | 16.19 | 3,555 | 57,555 | 62,769 | 66.3 K to 62.8 K (-5.36 %) |
Aug 27 2018 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | EVP, General Counse ... | Payment of Exercise | F | 24.60 | 1,473 | 36,236 | 51,381 | 52.9 K to 51.4 K (-2.79 %) |
Aug 08 2018 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Sell | S | 25.00 | 5,000 | 125,000 | 328,015 | 333 K to 328 K (-1.50 %) |
Jul 03 2018 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Payment of Exercise | F | 19.85 | 1,964 | 38,985 | 51,330 | 53.3 K to 51.3 K (-3.69 %) |
Jul 03 2018 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | Chief Medical Offic ... | Payment of Exercise | F | 19.85 | 2,161 | 42,896 | 49,475 | 51.6 K to 49.5 K (-4.19 %) |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Option Exercise | A | 24.45 | 7,543 | 184,426 | 7,543 | |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | Russell Lesley | Director | Grant | A | 0.00 | 3,578 | 0 | 24,913 | 21.3 K to 24.9 K (+16.77 %) |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Option Exercise | A | 24.45 | 7,543 | 184,426 | 7,543 | |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | PEREZ ROBERT J | Director | Grant | A | 0.00 | 3,578 | 0 | 21,113 | 17.5 K to 21.1 K (+20.40 %) |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Option Exercise | A | 24.45 | 7,543 | 184,426 | 7,543 | |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | Deptula Barbara | Director | Grant | A | 0.00 | 3,578 | 0 | 18,238 | 14.7 K to 18.2 K (+24.41 %) |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Option Exercise | A | 24.45 | 7,543 | 184,426 | 7,543 | |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | SULAT JAMES R | Director | Grant | A | 0.00 | 3,578 | 0 | 16,705 | 13.1 K to 16.7 K (+27.26 %) |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Option Exercise | A | 24.45 | 7,543 | 184,426 | 7,543 | |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | SANTINI GINO | Director | Grant | A | 0.00 | 3,578 | 0 | 23,088 | 19.5 K to 23.1 K (+18.34 %) |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Option Exercise | A | 24.45 | 7,543 | 184,426 | 7,543 | |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | Fallon John A. | Director | Grant | A | 0.00 | 3,578 | 0 | 18,977 | 15.4 K to 19 K (+23.24 %) |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Option Exercise | A | 24.45 | 7,543 | 184,426 | 7,543 | |
Jun 08 2018 | AVM | AMAG PHARMACEUTICA ... | SCOON DAVEY | Director | Grant | A | 0.00 | 3,578 | 0 | 25,513 | 21.9 K to 25.5 K (+16.31 %) |
Jun 05 2018 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | President & CEO | Sell | S | 25.00 | 20,000 | 500,000 | 333,015 | 353 K to 333 K (-5.67 %) |